Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:21:54 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ADPT - ADAPTIVE BIOTECHNOLOGIES CORP - http://www.adaptec.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ADPT - Q1.02.75·2.760.72.75+0.155.8303.17131,4602.65  2.765  2.629.0799  2.2811:03:00Apr 1715 min RT 2¢

Recent Trades - Last 10 of 1460
Time ETExPriceChangeVolume
11:03:00Q2.7550.15513
11:02:59Q2.75880.15881
11:02:44Q2.7550.15550
11:01:54Q2.750.15200
11:01:34Q2.750.15100
11:01:33Q2.750.151
11:01:33Q2.750.15228
11:01:33Q2.750.15100
11:01:33Q2.750.15100
11:01:33Q2.750.15100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-17 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
2024-04-02 16:05U:ADPTNews ReleaseAdaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
2024-03-27 08:30U:ADPTNews ReleaseAdaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
2024-02-22 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
2024-02-14 16:06U:ADPTNews ReleaseAdaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
2024-01-29 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
2023-12-27 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-09 08:31U:ADPTNews ReleaseAdaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ ‚ ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
2023-12-05 07:31U:ADPTNews ReleaseAdaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ ‚ ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
2023-11-09 16:05U:ADPTNews ReleaseAdaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
2023-11-07 07:31U:ADPTNews ReleaseAdaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ ‚ ® Assay Across BeiGene ¢ € ™s Lymphoid Malignancy Pipeline
2023-11-02 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
2023-09-13 07:31U:ADPTNews ReleaseAdaptive Announces Launch of Epic Integration for clonoSEQ ‚ ®
2023-08-30 16:30U:ADPTNews ReleaseAdaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-02 16:06U:ADPTNews ReleaseAdaptive Biotechnologies Reports Second Quarter 2023 Financial Results
2023-07-10 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
2023-06-02 07:35U:ADPTNews ReleaseAdaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ ‚ ® Assay ¢ € ™s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
2023-05-24 16:05U:ADPTNews ReleaseAdaptive Biotechnologies to Participate in Upcoming June Investor Conferences
2023-05-12 08:00U:ADPTNews ReleaseAdaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
2023-05-09 07:31U:ADPTNews ReleaseAdaptive Biotechnologies Announces FDA Acceptance of Genentech ¢ € ™s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology